Samson Assuta Ashdod University Hospital

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Diffuse large B-cell lymphoma2 trials
• Multiple myeloma2 trials
• Coronary artery disease1 trial
• Follicular lymphoma1 trial
• Head and neck cancer1 trial
• Lung cancer1 trial
• Myeloproliferative neoplasms1 trial
• Parkinson disease1 trial

Phase

• Phase 38 trials
• Phase 21 trial

Status

• Active, not recruiting4 trials
• Recruiting3 trials
• Completed2 trials
• Terminated1 trial

Lead sponsor

• Janssen Research & Development, LLC3 trials
• Regeneron Pharmaceuticals2 trials
• ADC Therapeutics S.A.1 trial
• CENTOGENE GmbH Rostock1 trial
• Gilead Sciences1 trial
• and 2 more

Running trials

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07266441· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Johnson & Johnson Enterprise Innovation Inc.· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT05089734· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04384484· Phase 3· ADC Therapeutics S.A.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Completed

  Rostock International Parkinson's Disease Study (ROPAD)

  NCT03866603· CENTOGENE GmbH Rostock· Source